Q-omics provides the consensus-scored LINC02829 profile across patient tissues and cancer cell-line models. LINC02829 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC02829 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, LINC02829 RNA expression shows 10,008 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, BLCA, and BRCA as cancer lineages where LINC02829 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02829 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02829 survival associations across molecular data types. LINC02829 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02829 RNA expression–survival associations across cancer types. High LINC02829 expression shows unfavorable associations in KIRP and READ, but favorable associations in LUAD, KIRC, SKCM and SARC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC02829 RNA expression.
This table summarizes LINC02829 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02829. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02829 shows lower tumor expression in BLCA, COAD, LUSC, LUAD and UCEC and higher tumor expression in LIHC. The BLCA box plot shows higher LINC02829 RNA expression in normal versus tumor tissue (log2 FC = −0.918, t-test p < 0.001).
This table shows molecular features associated with LINC02829 in patient tissues and cancer cell lines. In patient samples, LINC02829 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
